The immunophenotype of minimally differentiated acute myeloid leukemia (AML-MO): Reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors

Leukemia

Volumn 13, Issue 10, 1999, Pages 1513-1518

  Costello, R T ^a   Mallet, F ^a   Chambost, H ^b   Sainty, D ^a   Arnoulet, C ^a   Gastaut, J A ^a   Olive, D ^a,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b TIMONE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Acute myeloid leukemia; AML MO; CD34; CD38; Immune recognition; Leukemia progenitors

Indexed keywords

ANTILEUKEMIC AGENT; CD28 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOIMMUNITY; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; BLAST CELL; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLONOGENESIS; CYTOKINE RELEASE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOPHENOTYPING; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; TUMOR DIFFERENTIATION;

EID: 0032865742     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401519     Document Type: Article

References (38)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick H, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 626-629.
2. Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA. Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. Blood 1987; 70: 1400-1406.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991; 78: 325-329.
4. Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, Cox C, Dallapiccola B, Papa G. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood 1994; 83: 1619-1625.
5. Venditti A, Del Poeta G, Stasi R, Masi M, Bruno A, Buccisano F, Cox C, Coppetelli U, Aronica G, Simone MD. Minimally differentiated acute myeloid leukaemia (AML-M0): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases. Br J Haematol 1994; 88: 784-793.
6. Cohen PL, Hoyer JD, Kurtin PJ, Dewald GW, Hanson CA. Acute myeloid leukemia with minimal differentiation. A multiple parameter study. Am J Clin Pathol 1998; 109: 32-38.
7. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox MC, Stasi R, Bruno A, Aronica G, Maffei L, Suppo G, Simone MD, Forte L, Cordero V, Postorino M, Tuffilli V, Isacchi G, Masi M, Papa G, Amadori S. Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. Blood 1997; 89: 621-629.
8. Villamor N, Zarco M-A, Rozman M, Ribera J-M, Feliu E, Montserrat E. Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics. Leukemia 1998; 12: 1071-1075.
9. Brito-Babapulle F, Pullon H, Layton DM, Etches A, Huxtable A, Mangi M, Bellingham AJ, Mufti GJ. Clinicopathological features of acute undifferentiated leukaemia with a stem cell phenotype. Br J Haematol 1990; 76: 210-214.
10. Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuynck H, Van Orshoven A, Criel A, Stul M, Dal Cin P, Hernandez J. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood 1995; 85: 3688-3694.
11. Mavroudis D, Barrett J. The graft-versus-leukemia effect. Curr Opin Hematol 1996; 3: 423-429.
12. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
13. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995; 345: 1144-1146.
14. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick J. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
15. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 1997; 3: 730-737.
16. -. Blood 1998; 92: 4325-4335.
17. + subpopulations. Blood 1995; 86: 2906-2912.
18. -) in acute myeloid leukaemia. Blood 1995; 86: 1139-1147.
19. Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38-progenitor cells. Blood 1991; 77: 1218-1227.
20. Buccheri V, Matutes E, Dyer MJS, Catovsky D. Lineage commitment in biphenoptypic acute leukemia. Leukemia 1993; 7: 919-927.
21. Costello R, Cerdan C, Pavon C, Brailly H, Hurpin C, Mawas C, Olive D. The CD2 and CD28 adhesion molecules induce long-term autocrine proliferation of CD4+ T cells. Eur J Immunol 1993; 23: 608-613.
22. Anonymous (1993). SPSS User's Guide. SPSS Inc: Chicago, IL.
23. Costello RT, Mallet F, Sainty D, Maraninchi D, Gastaut JA, Olive D. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur J Immunol 1998; 28: 90-103.
24. Freedman AS, Freeman GJ, Rhynhart K, Nadler LM. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 1991; 137: 429-437.
25. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993; 366: 76-79.
26. Hirano N, Takahashi T, Ohtake S, Hirashima K, Emi N, Saito K, Hirano M, Shinoara K, Takeuchi M, Taketazu F, Tsunoda S, Ogura M, Omine M, Saito T, Yazaki Y, Ueda R, Hirai H Expression of costimulatory molecules in human leukemias. Leukemia 1996; 10: 1168-1176.
27. + progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 1998; 95: 10152-10157.
28. Matutes E, Rodriguez B, Polli N. Characterization of myeloid leukaemias with monoclonal antibodies 3C5 and My9(CD33). Hematol Oncol 1985; 3: 179-186.
29. Helleberg C, Knudsen H, Hansen PB, Nikolajsen K, Kjaersgaard E, Ralfkiaer E, Johnsen HE. CD34+ megakaryoblastic leukaemic cells are CD38-, but CD61+ and glycophorin A+: improved criteria for diagnosis of AML-M7? Leukemia 1997; 11: 830-834.
30. Rondelli D, Andrews RG, Hansen JA, Ryncarz R, Faerber MA, Anasetti C. Alloantigen presenting function of normal human CD34+ hematopoietic cells. Blood 1996; 88: 2619-2625.
31. Ryncarz RE, Anasetti C. Expression of CD86 on human marrow CD34(+) cells identifies immunocompetent committed precursors of macrophages and dendritic cells. Blood 1998; 91: 3892-3900.
32. Costello RT, Gastaut J-A, Olive D. Tumour escape from immune surveillance. Arch Immunol Ther Exp (Warsz) 1999; 47: 83-88.
33. Costello RT, Gastaut J-A, Olive D. What is the real role of CD40 in cancer immunotherapy? Immunol Today 1999 (in press).
34. Costello RT, Mallet F, Chambost H, Sainty D, Gastaut J-A, Olive D. Differential modulation of immune recognition molecules by interleukin-7 in human acute leukaemias. Eur Cytokine Netw 1999; 10: 87-95.
35. Terstappen LW, Safford M, Unterhalt M, Könemann S, Zurlutter K, Piechotka K, Drescher M, Aul C, Büchner T, Hiddemann W, Wörmann B. Flow cytometry characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia 1992; 6: 993-1000.
36. Borowitz MJ, Gockerman JP, Moore JO, Civin CI, Page SO, Robertson J, Bigner SH. Clinicopathologic and cytogenetic features of CD34(My 10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol 1989; 91: 265-270.
37. Borowitz MJ, Shuster JJ, Civin CI, Caroll AJ, Look AT, Behm FG, Land VJ, Pullen DJ, Crist WM. Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 1990; 8: 1389-1398.
38. Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, Piantadosi S, Civin CI. Prognostic significance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34(My 10). Br J Haematol 1990; 76: 340-347.